...
gmab-img

Genmab AS, Common Stock

GMAB

NSQ

$20.31

+$0.22

(1.1%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$12.79B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
19.7451
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.82M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.86
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$19.85 L
$32.88 H
$20.31

About Genmab AS, Common Stock

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameGMABSectorS&P500
1-Week Return0.69%-2.12%-3%
1-Month Return-0.68%-3.42%-0.73%
3-Month Return-20.45%-11.13%2.87%
6-Month Return-21.52%-5.74%7.17%
1-Year Return-33.54%3.97%25.31%
3-Year Return-47.7%1.05%28.38%
5-Year Return-6.41%34.37%81.89%
10-Year Return238.61%97.88%183.27%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue5.37B10.11B8.48B14.60B16.47B[{"date":"2019-12-31","value":32.57,"profit":true},{"date":"2020-12-31","value":61.38,"profit":true},{"date":"2021-12-31","value":51.49,"profit":true},{"date":"2022-12-31","value":88.59,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue----226.00M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit5.37B10.11B8.48B14.60B16.25B[{"date":"2019-12-31","value":33.03,"profit":true},{"date":"2020-12-31","value":62.23,"profit":true},{"date":"2021-12-31","value":52.2,"profit":true},{"date":"2022-12-31","value":89.83,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin100.00%100.00%100.00%100.00%98.63%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.63,"profit":true}]
Operating Expenses2.73B3.80B5.46B8.24B10.93B[{"date":"2019-12-31","value":24.97,"profit":true},{"date":"2020-12-31","value":34.76,"profit":true},{"date":"2021-12-31","value":50,"profit":true},{"date":"2022-12-31","value":75.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income2.64B6.31B3.02B6.36B5.32B[{"date":"2019-12-31","value":41.5,"profit":true},{"date":"2020-12-31","value":99.31,"profit":true},{"date":"2021-12-31","value":47.48,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.7,"profit":true}]
Total Non-Operating Income/Expense555.00M(235.00M)1.15B1.07B1.23B[{"date":"2019-12-31","value":45.2,"profit":true},{"date":"2020-12-31","value":-19.14,"profit":false},{"date":"2021-12-31","value":93.57,"profit":true},{"date":"2022-12-31","value":87.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income2.86B5.90B3.98B7.04B5.64B[{"date":"2019-12-31","value":40.64,"profit":true},{"date":"2020-12-31","value":83.92,"profit":true},{"date":"2021-12-31","value":56.62,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.13,"profit":true}]
Income Taxes693.00M1.15B975.00M1.51B1.28B[{"date":"2019-12-31","value":45.8,"profit":true},{"date":"2020-12-31","value":75.74,"profit":true},{"date":"2021-12-31","value":64.44,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":84.93,"profit":true}]
Income After Taxes2.17B4.76B3.01B5.52B4.35B[{"date":"2019-12-31","value":39.22,"profit":true},{"date":"2020-12-31","value":86.16,"profit":true},{"date":"2021-12-31","value":54.47,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":78.81,"profit":true}]
Income From Continuous Operations2.17B4.76B3.01B5.52B4.35B[{"date":"2019-12-31","value":39.22,"profit":true},{"date":"2020-12-31","value":86.16,"profit":true},{"date":"2021-12-31","value":54.47,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":78.81,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income2.17B4.76B2.96B5.45B4.35B[{"date":"2019-12-31","value":39.73,"profit":true},{"date":"2020-12-31","value":87.27,"profit":true},{"date":"2021-12-31","value":54.24,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":79.82,"profit":true}]
EPS (Diluted)4.868.150.731.170.96[{"date":"2019-12-31","value":59.6,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":8.96,"profit":true},{"date":"2022-12-31","value":14.36,"profit":true},{"date":"2023-12-31","value":11.78,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

GMAB
Cash Ratio 3.78
Current Ratio 5.17
Quick Ratio 5.15

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

GMAB
ROA (LTM) 10.95%
ROE (LTM) 14.92%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

GMAB
Debt Ratio Lower is generally better. Negative is bad. 0.20
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.80

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

GMAB
Trailing PE 19.75
Forward PE 13.79
P/S (TTM) 0.64
P/B 2.85
Price/FCF 6
EV/R 3.75
EV/Ebitda 10.67
PEG 0.70

FAQs

What is Genmab AS share price today?

Genmab AS (GMAB) share price today is $20.31

Can Indians buy Genmab AS shares?

Yes, Indians can buy shares of Genmab AS (GMAB) on Vested. To buy Genmab AS from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GMAB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Genmab AS be purchased?

Yes, you can purchase fractional shares of Genmab AS (GMAB) via the Vested app. You can start investing in Genmab AS (GMAB) with a minimum investment of $1.

How to invest in Genmab AS shares from India?

You can invest in shares of Genmab AS (GMAB) via Vested in three simple steps:

  • Click on Sign Up or Invest in GMAB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Genmab AS shares
What is Genmab AS 52-week high and low stock price?

The 52-week high price of Genmab AS (GMAB) is $32.88. The 52-week low price of Genmab AS (GMAB) is $19.85.

What is Genmab AS price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Genmab AS (GMAB) is 19.7451

What is Genmab AS price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Genmab AS (GMAB) is 2.85

What is Genmab AS dividend yield?

The dividend yield of Genmab AS (GMAB) is 0.00%

What is the Market Cap of Genmab AS?

The market capitalization of Genmab AS (GMAB) is $12.79B

What is Genmab AS’s stock symbol?

The stock symbol (or ticker) of Genmab AS is GMAB

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top